Evidence map›Paper›PMID 40248731›Full record

ReviewTranslational lung cancer research2025

Recent advancements in lung cancer research: a narrative review.

Fuk Hay Tang, Heylie Y T Wong, Phyllis S W Tsang, Mabel Yau, Shing Yau Tam, Lawla Law, Katherine Yau, Jade Wong, Fatema Hassan Mustafa Farah, Jacky Wong

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pre-treatment quality of life and survival outcomes in lung cancer patients: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Resveratrol-EnrichedNutrients · 2026
    Article
  10. Article
  11. CCR5 expression defines the functional heterogeneity of tumor-infiltrating CD8Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  12. Article
  13. Article
  14. Comparison of PD-L1 expression between biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Assessing Respiratory Motion Stability of NovelDiagnostics (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fuk Hay Tang *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Heylie Y T Wong *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Phyllis S W Tsang *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Mabel Yau *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Shing Yau Tam *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Lawla Law *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Katherine Yau *School of Nursing, Tung Wah College, Hong Kong, China.
Jade Wong *Library, Tung Wah College, Hong Kong, China.
Fatema Hassan Mustafa Farah *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.
Jacky Wong *School of Medical and Health Sciences, Tung Wah College, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, with a 5-year survival rate ranging from 10% to 20%. The majority of cases are categorized as non-small cell lung cancer (NSCLC) (80%) and small cell lung cancer (SCLC) (20%), with NSCLC being the more prevalent type. Tobacco use, particularly cigarette smoking, is a significant contributor to over 80% of lung cancer cases. Early diagnosis is challenging due to limitations in screening methods, resulting in many cases being identified only in advanced stages. Moreover, current treatment options often exhibit low efficacy, partly due to an inadequate understanding of the disease's pathogenesis. This narrative review aims to summarize recent discoveries and advancements in lung cancer research, focusing on improvements in diagnosis, treatment, and understanding of the disease. Methods: A comprehensive literature review was performed utilizing the PubMed Central database to identify recent studies relevant to lung cancer. This review synthesizes findings from various research articles to provide a cohesive summary of advancements in the field. Key Content and Findings: In the past decade, notable progress has been achieved in lung cancer research, particularly concerning diagnostics and treatment strategies. Novel therapeutic approaches, including immunotherapy and genomic-targeted therapies, have demonstrated promising results. Understanding the tumor microenvironment (TME) and the role of T lymphocytes has become crucial for developing effective treatments. Additionally, advancements in immune checkpoint inhibitors (ICIs) have shown potential in enhancing patient outcomes. Improvements in tumor detection technologies are also anticipated to facilitate earlier diagnosis, ultimately contributing to better survival rates. Conclusions: Significant strides have been made in lung cancer research over the last ten years, particularly in diagnostics and treatment methodologies. Future research should prioritize exploring the TME, the function of T lymphocytes, and the efficacy of ICIs while continuing to innovate in tumor detection technologies. Such efforts are essential for enhancing treatment outcomes and improving the overall quality of life for lung cancer patients.

Indexed as

early detectionLung cancerscreeningtreatmenttumor microenvironment (TME)

Identifiers

PMID40248731
PMCPMC12000946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.